Clene Inc (CLNNW) - Net Assets
Based on the latest financial reports, Clene Inc (CLNNW) has net assets worth $-12.36 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.31 Million) and total liabilities ($34.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Clene Inc (CLNNW) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.36 Million |
| % of Total Assets | -55.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -2697.36% |
| 10-Year Change | N/A |
| Growth Volatility | 1349.78 |
Clene Inc - Net Assets Trend (2017–2024)
This chart illustrates how Clene Inc's net assets have evolved over time, based on quarterly financial data. Also explore CLNNW total asset value for the complete picture of this company's asset base.
Annual Net Assets for Clene Inc (2017–2024)
The table below shows the annual net assets of Clene Inc from 2017 to 2024. For live valuation and market cap data, see Clene Inc (CLNNW) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-8.86 Million | -166.15% |
| 2023-12-31 | $13.39 Million | +313.65% |
| 2022-12-31 | $3.24 Million | -74.30% |
| 2021-12-31 | $12.60 Million | +3594.13% |
| 2020-12-31 | $341.00K | -93.02% |
| 2019-12-31 | $4.89 Million | -2.26% |
| 2018-12-31 | $5.00 Million | +209305.06% |
| 2017-12-31 | $-2.39K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Clene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28212061000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $71.00K | % |
| Other Components | $273.19 Million | % |
| Total Equity | $-8.86 Million | 100.00% |
Clene Inc Competitors by Market Cap
The table below lists competitors of Clene Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
$17.52 |
|
Ordinary Fully Paid Deferred Settlement
AU:1TTDB
|
$20.45 |
|
Arko Corp
NASDAQ:ARKOW
|
$23.76 |
|
US Solar Fund PLC
LSE:USFP
|
$24.60 |
|
Lexaria Bioscience Corp
NASDAQ:LEXXW
|
$11.02 |
|
Aquis Exchange PLC
LSE:AQX
|
$10.66 |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
$8.89 |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
$6.51 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Clene Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,390,000 to -8,857,000, a change of -22,247,000 (-166.1%).
- Net loss of 39,400,000 reduced equity.
- New share issuances of 9,243,000 increased equity.
- Other comprehensive income decreased equity by 128,000.
- Other factors increased equity by 8,038,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.40 Million | -444.85% |
| Share Issuances | $9.24 Million | +104.36% |
| Other Comprehensive Income | $-128.00K | -1.45% |
| Other Changes | $8.04 Million | +90.75% |
| Total Change | $- | -166.15% |
Book Value vs Market Value Analysis
This analysis compares Clene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $1.60 | $0.00 | x |
| 2019-12-31 | $1.41 | $0.00 | x |
| 2020-12-31 | $0.10 | $0.00 | x |
| 2021-12-31 | $4.09 | $0.00 | x |
| 2022-12-31 | $0.99 | $0.00 | x |
| 2023-12-31 | $2.55 | $0.00 | x |
| 2024-12-31 | $-1.27 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Clene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11520.47%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-920.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.15K |
| 2018 | -5.55% | 0.00% | 0.00x | 9.43x | $-777.31K |
| 2019 | -330.57% | 0.00% | 0.00x | 3.04x | $-16.64 Million |
| 2020 | -5653.08% | -9357.77% | 0.00x | 200.13x | $-19.31 Million |
| 2021 | -77.32% | -1347.16% | 0.01x | 5.01x | $-11.00 Million |
| 2022 | -924.25% | -6325.16% | 0.01x | 13.75x | $-30.24 Million |
| 2023 | -369.71% | -7569.42% | 0.01x | 3.91x | $-50.84 Million |
| 2024 | 0.00% | -11520.47% | 0.01x | 0.00x | $-38.51 Million |
Industry Comparison
This section compares Clene Inc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Clene Inc (CLNNW) | $-12.36 Million | 0.00% | N/A | $16.32 |
| Advent Technologies Holdings Inc (ADNWW) | $130.20 Million | -15.76% | 0.25x | $27.01 |
| AmpliTech Group Inc (AMPGW) | $91.07K | -845.48% | 3.88x | $751.88 |
| Arko Corp (ARKOW) | $72.92 Million | -5.21% | 3.05x | $23.76 |
| Aris Mining Corporation (ARMN) | $-623.73K | 0.00% | 0.00x | $3.93 Billion |
| Aberdeen Standard Global Infrastructure Income Fund (ASGI) | $172.37 Million | 0.00% | 0.01x | $472.62 Million |
| Atlas Corp (ATCOL) | $523.44 Million | 2.74% | 0.24x | $249.71K |
| Auddia Inc (AUUDW) | $9.41 Million | -232.98% | 0.02x | $394.90 |
| BriaCell Therapeutics Corp (BCTXW) | $11.79 Million | -9.15% | 0.05x | $8.89 |
| Blaize Holdings, Inc. Warrants (BZAIW) | $-70.54 Million | 0.00% | 0.00x | $4.00 Million |
| Churchill Capital Corp IX Warrant (CCIXW) | $6.04K | -313.77% | 9.82x | $14.04 Million |
About Clene Inc
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis … Read more